Search Results

You are looking at 41 - 50 of 362 items for :

  • "therapeutics" x
  • Refine by Access: All x
Clear All
Full access

YIA20-006: Preclinical Pediatric MATCH

Elizabeth Stewart, Kaley Blankenship, Lauren Hoffmann, and Burgess Freeman

presented at the annual meeting. Conclusions: The testing of molecularly targeted therapeutics in PDX models of pediatric solid tumors is feasible and may be beneficial to understanding the driver mutations and underlying biology of these malignancies. We

Full access

EPR21-039: Socioeconomic Disparities in Receipt of Care in Lung Cancer

Evangelia Valilis, Catherine Yip, Laura Prichett, Catherine Burdalski, and Josephine Feliciano

care. This study aimed to evaluate the association of socio-demographic factors with lung cancer treatment at a large academic center that serves a diverse patient population. In the era of improved outcomes related to improved therapeutics such as

Full access

A “Shot Heard ’Round the World” on Cancer Drug Costs?

Harold J. Burstein

Recently, members of the pharmacy and therapeutics committee at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York reported that MSKCC will not offer ziv-aflibercept (Zaltrap, Sanofi Oncology) to patients with advanced colorectal cancer at

Full access

The Time Has Come!

Margaret Tempero

When imatinib was approved by the FDA almost 20 years ago, a passionate prediction arose that, going forward, all targeted therapeutics would be approved without regard for the primary site of disease, based solely on the presumed molecular driver

Full access

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Floor J. Backes, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Gary Leiserowitz, Joyce Liu, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac-Lima, Steven W. Remmenga, John Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsiros, Mary A. Dwyer, and Lisa Hang

receiving consulting fees from Seagen Inc. David M. Gershenson, MD, Panel Member, has disclosed serving as a scientific advisor for Genentech, Inc., Onconova Therapeutics, and Verastem Oncology; owning equity interest/stock options in Bristol-Myers Squibb

Full access

Research Priorities in Geriatric Oncology: Addressing the Needs of an Aging Population

Arti Hurria, Supriya Gupta Mohile, and William Dale

rationale for these research directions. Cancer Therapeutics in the Oldest Adults (Ages 75 and Older) Among FDA-approved treatments for cancer, only 9% of patients enrolled in registration trials were 75 years or older, whereas 31% of patients with

Full access

Fatigue is the Most Important Symptom for Advanced Cancer Patients Who Have Had Chemotherapy

Zeeshan Butt, Sarah K. Rosenbloom, Amy P. Abernethy, Jennifer L. Beaumont, Diane Paul, Debra Hampton, Paul B. Jacobsen, Karen L. Syrjala, Jamie H. Von Roenn, and David Cella

, Bristol-Myers Squibb, Centocor, Cell Therapeutics, Inc., Genentech, GlaxoSmithKline, Eli Lilly and Company, Merck & Co., Novartis, Ortho Biotech, Pfizer, sanofi-aventis, and Takeda Pharmaceuticals. References 1. Cella DF Tulsky DS Gray G

Full access

Express Scripts? Really?

Margaret Tempero

Acorda Therapeutics, which is offered to patients free for 2 months before any charges begin. This model makes sense to me. I'm certainly not an expert in commercial enterprise, but I would think a company could shape a business model around this. And I

Full access

Oncology Research Program

survival, and development of novel therapeutics has been met with little success. Although immunotherapeutics have shown promise in this devastating disease, most patients do not derive a benefit and a sizable population are not candidates for this therapy

Full access

Oncology Research Program

metastatic head and neck squamous cell carcinoma (R/M HNSCC) has a dismal survival rate, and development of novel therapeutics has been met with little success. Although immunotherapeutics have shown promise in this devastating disease, most patients do not